Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Molecure.

    Client Virtual Booth

    MOLECURE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Molecure
    Poland Flag
    Country
    Country
    Poland
    Address
    Address
    Żwirki i Wigury 101, 02-089 Warsaw
    Telephone
    Telephone
    +48 (22) 552 67 24
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://molecure.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/molecure-sa/
    Twitter
    Twitter
    https://twitter.com/molecure_sa

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    First Patient in the UK is Dosed in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

    Details:

    OATD-01 is an oral, small molecule inhibitor of chitinase-1 (CHIT1), which is being evaluated for the treatment of patients with acute pulmonary sarcoidosis.


    Lead Product(s): OATD-01

    Therapeutic Area: Immunology Product Name: OATD-01

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    The U.S. Food and Drug Administration Gives the Green Light to Molecure's Flagship Program Phase II Clinical Testing of OATD-01 is Ready for Launch

    Details:

    OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.


    Lead Product(s): OATD-01

    Therapeutic Area: Immunology Product Name: OATD-01

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarc...

    Details:

    OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.


    Lead Product(s): OATD-01

    Therapeutic Area: Immunology Product Name: OATD-01

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Galapagos

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Molecure To Regain Worldwide Rights to Dual Chitinase Inhibitor OATD-01

    Details:

    Molecure has regained (at no cost) the full and exclusive rights to the results of all research, pre-clinical and clinical development performed by Galapagos with OATD-01 over the course of the last 18 months.


    Lead Product(s): OATD-01

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Galapagos

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership June 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search